Frequency of the TAFI –438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism

Summary

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are considered to be two forms of the same disease, however it is not fully understood what determines their clinical presentation.

Proteins encoded by the FXIIIA and TAFI genes are involved in stabilizing the fibrin clot and in making it more lysis resistant. The FXIIIA 34Leu and TAFI –438A alleles might protect against DVT. Information on such an association with PE is either contradictory or missing. We hypothesized that both polymorphisms might influence the formation and fate of emboli and accordingly the risk of PE. We determined the frequencies of both polymorphisms in patients with objectively demonstrated PE.

The frequency of FXIIIA Leu34Leu in PE patients and non-PE patients was 4.5% and 8.8%, [OR 0.5 (95% CI: 0.1 to 1.9)], respectively. For –438 A/A TAFI genotype the frequency was 1.5% and 8.1% [OR 0.1 (95% CI: 0.02 to 1.1)], respectively.

Keywords

Pulmonary embolism - thrombin activatable fibrinolysis inhibitor (TAFI) / carboxypeptidases - Factor XIII / transglutaminases

• References

• 1 Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance – Astrup revisited. Haemostasis 1999; 29 (01) 58-71.
• 2 Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82 (02) 601-9.
• 3 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 6475 64-7.
• 4 Ridker PM, Miletich JP, Hennekens CH. et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277 (16) 1305-7.
• 5 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346 8983 1133-4.
• 6 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-703.
• 7 Balogh I, Szoke G, Karpati L. et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96 (07) 2479-86.
• 8 Corral J, Gonzalez-Conejero R, Iniesta JA. et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85 (03) 293-7.
• 9 Franco RF, Reitsma PH, Lourenco D. et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81 (05) 676-9.
• 10 Catto AJ, Kohler HP, Coore J. et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93 (03) 906-8.
• 11 Alhenc-Gelas M, Reny JL, Aubry ML. et al. The FXIII Val 34 Leu mutation and the risk of venous thrombosis. [letter] . Thromb Haemost 2000; 84 (06) 1117-8.
• 12 van Hylckama Vlieg A, Komanasin N, Ariëns RAS. et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119 (01) 169-75.
• 13 Franco RF, Fagundes MG, Meijers JC. et al. Identification of polymorphisms in the 5’-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86 (05) 510-7.
• 14 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94 (05) 271-305.
• 15 Kohler HP, Ariëns RA, Whitaker P. et al. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. [letter]. Thromb Haemost 1998; 80 (04) 704.
• 16 Wartiovaara U, Mikkola H, Szoke G. et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84 (04) 595-600.
• 17 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92 (08) 2766-70.
• 18 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275 (27) 20627-31.
• 19 Ariëns RA, Philippou H, Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (03) 988-95.
• 20 Atwa AAA, Grant PJ, Ariëns RAS.. Effect of the FXIII Val34Leu polymorphism on the interaction between platelets and cross-linked fibrin. Thromb Haemost (suppl.). 2001 (abstract)
• 21 Ariëns RAS, Collet PJ, Grant PJ. et al. Effect of the FXIII Val34Leu polymorphism on the structure and elastic properties of fibrin clots and on fibrinolysis rates. Thromb Haemost (suppl.). 2001 (abstract)
• 22 Ehrenforth S, Zwinge B, Krause M. et al. Association between the Val34Leu polymorphism of factor XIII gene and pulmonary embolism. Thromb Haemost (suppl.). 2001 (abstract)
• 23 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20 (12) 2511-8.
• 24 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95 (09) 2855-9.
• 25 Henry M, Aubert H, Morange PE. et al. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97 (07) 2053-8.
• 26 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels [letter]. Blood 2001; 98 (06) 1992-3.
• 27 de Monyé W, van Strijen MJ, Huisman MV. et al. Suspected pulmonary embolism: prevalence and anatomic distribution in 487 consecutive patients. Advances in New Technologies Evaluating the Localisation of Pulmonary Embolism (ANTELOPE) Group. Radiology 2000; 215 (01) 184-8.
• 28 Lensing AW, van Beek EJ, Demers C. et al. Ventilation-perfusion lung scanning and the diagnosis of pulmonary embolism: improvement of observer agreement by the use of a lung segment reference chart. Thromb Haemost 1992; 68 (03) 245-9.
• 29 Hull RD, Hirsh J, Carter CJ. et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88 (06) 819-28.
• 30 Woolf B. On estimating the relation between group and disease. Am J Hum Genet 1955; 19: 251-3.
• 31 Huisman MV, Büller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95 (03) 498-502.
• 32 Nielsen HK, Husted SE, Krusell LR. et al. Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994; 235 (05) 457-61.
• 33 Monreal M, Rey-Joly BC, Ruiz MJ. et al. Asymptomatic pulmonary embolism in patients with deep vein thrombosis. Is it useful to take a lung scan to rule out this condition?. J Cardiovasc Surg (Torino) 1989; 30 (01) 104-7.